About Pirtobrutinib API
Therapeutic CategoryAnti-Cancer/ Oncology

CAS Number
2101700-15-4
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under Development
Mechanism of Action
Pirtobrutinib binds reversibly to the BTK protein in the ATP pocket and does not depend on C481. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations. A visualization of pirtobrutinib binding reversibly to the BTK protein with an exploded view showing the ATP pocket.
Indication
Pirtobrutinib is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
Related APIs
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.